

IDS - 06/12/2006

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10567801
Filing Date	2006-02-09
First Named Inventor	Bennett
Art Unit	
Examiner Name	Not yet assigned
Attorney Docket Number	101181-1P US

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
SY	1	3706810		1972-12-19	American Cyanamid Company	
SY	2	4599198		1986-07-08	Pfizer Inc.	
SY	3	4668769		1987-05-26	Dennis J. Hoover	
SY	4	4692522		1987-09-08	Merck & Co., Inc.	
SY	5	4720503		1988-01-19	Merck & Co., Inc.	
SY	6	4751231		1988-06-14	Merck & Co., Inc.	
SY	7	4786641		1988-11-22	Bayer Aktiengesellschaft	
SY	8	4794120		1988-12-27	Synthelabo	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10567801
Filing Date	2006-02-09
First Named Inventor	Stuart Norman Lile Bennett
Art Unit	1626
Examiner Name	Young, Shawquia
Attorney Docket Number	101181-1P US

/SY/	1	S. FREEMAN et al, Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme, British Journal of Pharmacology, 2006, 775-785, 149	<input type="checkbox"/>
------	---	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Shawquia Young/	Date Considered	03/26/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10567801
Filing Date		2006-02-09
First Named Inventor	Bennett	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101181-1P US	

SY	9	5863903		1999-01-26	Novo Nordisk A/S	
SY	10	5998463		1999-12-07	Pfizer Inc.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
SY	1	200740	DD	A	1983-06-08	Karl Gewald et. al.		<input checked="" type="checkbox"/>
SY	2	4445968	DE	A1	1996-06-27	Bayer AG		<input checked="" type="checkbox"/>
SY	3	0697403	EP	A1	1996-02-21	Sanofi		<input checked="" type="checkbox"/>
SY	4	0846464	EP	A2	1998-06-10	Pfizer Inc		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10567801
Filing Date		2006-02-09
First Named Inventor	Bennett	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number		101181-1P US

SY	5	0884050	EP	A1	1998-12-16	Novo Nordisk A/S		<input type="checkbox"/>
SY	6	0978279	EP	A1	2000-02-09	Pfizer Products Inc.		<input type="checkbox"/>
SY	7	1088824	EP	A2	2001-04-04	Pfizer Products Inc.		<input type="checkbox"/>
SY	8	1125580	EP	A2	2001-08-22	Pfizer Products Inc.		<input type="checkbox"/>
SY	9	1134213	EP	A2	2001-09-19	Pfizer Inc.		<input type="checkbox"/>
SY	10	1136071	EP	A2	2001-09-26	Pfizer Products Inc.		<input type="checkbox"/>
SY	11	1145717	EP	A2	2001-10-17	Pfizer Products Inc.		<input type="checkbox"/>
SY	12	1149580	EP	A1	2001-10-31	Pfizer Products Inc.		<input type="checkbox"/>
SY	13	1177791	EP	A2	2002-02-06	Pfizer Products Inc.		<input type="checkbox"/>
SY	14	1340500	EP	A1	2003-09-03	Pfizer Products Inc		<input type="checkbox"/>
SY	15	2081747	ES	A1	1996-03-01	Laboratories del Dr. Esteve, S.A.		<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10567801
Filing Date		2006-02-09
First Named Inventor	Bennett	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101181-1P US	

SY	16	04179949	JP	A	1992-06-26	Fuji Photo Film CO., Ltd.	<input checked="" type="checkbox"/>
SY	17	2001 089368	JP	A	2001-04-03	Tanabe Seiyaku Co., Ltd	<input checked="" type="checkbox"/>
SY	18	2001 206856	JP	A	2001-07-31	Pfizer Products Inc.	<input checked="" type="checkbox"/>
SY	19	2001 247565	JP	A	2001-09-11	Pfizer Products Inc	<input checked="" type="checkbox"/>
SY	20	2004 196702	JP	A	2004-07-15	Yamanouchi Pharmaceuticals Co., Ltd.	<input checked="" type="checkbox"/>
SY	21	93/25574	WO	A1	1993-12-23	Pfizer Inc.	<input type="checkbox"/>
SY	22	95/24391	WO	A1	1995-09-14	Novo Nordisk A/S	<input type="checkbox"/>
SY	23	96/39384	WO	A1	1996-12-12	Pfizer Inc.	<input type="checkbox"/>
SY	24	96/39385	WO	A1	1996-12-12	Pfizer Inc.	<input type="checkbox"/>
SY	25	97/09040	WO	A1	1997-03-13	Novo Nordisk	<input type="checkbox"/>
SY	26	97/31901	WO	A1	1997-09-04	Mikael Bols	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10567801
Filing Date		2006-02-09
First Named Inventor	Bennett	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101181-1P US	

SY	27	97/45425	WO	A1	1997-12-04	Fujisawa Pharmaceutical Co., Ltd.		<input type="checkbox"/>
SY	28	98/27108	WO	A2	1998-06-25	Fujisawa Pharmaceutical Co., Ltd.		<input type="checkbox"/>
SY	29	98/40353	WO	A1	1998-09-17	Novo Nordisk A/S		<input type="checkbox"/>
SY	30	98/50359	WO	A1	1998-11-12	Novo Nordisk A/S		<input type="checkbox"/>
SY	31	99/26659	WO	A1	1999-06-03	Pfizer Products Inc.		<input type="checkbox"/>
SY	32	99/36393	WO	A1	1999-07-22	Tanabe Seiyaku Co., Ltd.		<input type="checkbox"/>
SY	33	00/42213	WO	A1	2000-07-20	The Research Foundation of State University of NY		<input type="checkbox"/>
SY	34	00/47206	WO	A1	2000-08-17	Novo Nordisk A/S		<input type="checkbox"/>
SY	35	01/05954	WO	A1	2001-01-25	Isis Pharmaceuticals Inc		<input type="checkbox"/>
SY	36	01/23347	WO	A1	2001-04-05	Novo Nordisk A/S		<input type="checkbox"/>
SY	37	01/32622	WO	A1	2001-05-10	AstraZeneca AB		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10567801
Filing Date		2006-02-09
First Named Inventor	Bennett	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101181-1P US	

SY	38	01/32654	WO	A2	2001-05-10	Societe de Conseils de Recherches et D'App Sci	<input checked="" type="checkbox"/>
SY	39	01/52825	WO	A2	2001-07-26	Novartis AG	<input type="checkbox"/>
SY	40	01/68055	WO	A1	2001-09-20	Pfizer Products Inc.	<input type="checkbox"/>
SY	41	01/68092	WO	A2	2001-09-20	Pfizer Products Inc.	<input type="checkbox"/>
SY	42	01/68603	WO	A2	2001-09-20	Bristol-Myers Squibb Co.	<input type="checkbox"/>
SY	43	01/94300	WO	A1	2001-12-13	Aventis Pharma Deutschland GMBH	<input checked="" type="checkbox"/>
SY	44	01/96311	WO	A2	2001-12-20	Bristol-Myers Squibb Company	<input type="checkbox"/>
SY	45	01/96347	WO	A1	2001-12-20	Bristol-Myers Squibb Company	<input type="checkbox"/>
SY	46	02/20530	WO	A1	2002-03-14	AstraZeneca AB	<input type="checkbox"/>
SY	47	02/26714	WO	A1	2002-04-04	Takeda Chemical Industries	<input checked="" type="checkbox"/>
SY	48	02/34718	WO	A1	2002-05-02	Richter Gedeon Vegyeszeti Gyar RT	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10567801
Filing Date		2006-02-09
First Named Inventor	Bennett	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101181-1P US	

SY	49	02/36583	WO	A1	2002-05-10	Shionogi & Co., Ltd.	<input checked="" type="checkbox"/>
SY	50	02/80844	WO	A2	2002-10-17	Genzyme Corporation	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
SY	1	CROCHET R.A., et al., J. Het. Chem., "Synthesis of Substituted Thieno[2,3-b] pyrroles," April 1974, 143-150, Vol. 11.	<input type="checkbox"/>
SY	2	HARTMAN G.D., et al., "The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides," Heterocycles, 1989, 1943-1949, Vol. 29(10).	<input type="checkbox"/>
SY	3	MCCORMACK J.G., et al., "Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy," Curr. Pharmaceutical Design, 2001, 1451-1474, Vol. 7.	<input type="checkbox"/>
SY	4	JAKOBSEN P., et al., "Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase.," Bioorganic Med. Chem., 2001, 733-744, Vol. 9.	<input type="checkbox"/>
SY	5	TREADWAY J.L., et al., "Glycogen phosphorlase inhibitors for treatment of type 2 diabetes mellitus," Exp. Opin. Invest. Drugs, 2001, 439-454, Vol. 10(3).	<input type="checkbox"/>
SY	6	RATH V.L. et al., "Activation of Human Liver Glycogen Phosphorylase by Alteration of the Secondary Structure and Packing of the Catalytic Core," Mol. Cell, July 2000, 139-148, Vol. 6.	<input type="checkbox"/>
SY	7	OIKONOMAKOS N.G., et al., "Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate," Protein Sci., 1999, 1930-1945, Vol. 8.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10567801
Filing Date	2006-02-09
First Named Inventor	Bennett
Art Unit	
Examiner Name	Not yet assigned
Attorney Docket Number	101181-1P US

SY	8	VENKATARANGAN P., et al., "Prediction of Ligand-Receptor Binding Thermodynamics by Free Energy Force Field Three-Dimensional Quantitative Structure-Activity Relationship Analysis: Applications to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase," J. Med. Chem., 1999, 2169-2179, Vol. 42.	<input type="checkbox"/>
SY	9	HOOVER D.J., et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase," J. Med. Chem., 1998, 2934-2938, Vol. 41.	<input type="checkbox"/>
SY	10	MARTIN W.H., et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo," PNAS, Feb. 1998, 1776-1781, Vol. 95.	<input type="checkbox"/>
SY	11	SOMAN G., et al., "The Nature of the Binding Site for Aromatic Compounds in Glycogen Phosphorylase b," Biochem. J., 1975, 369-371, Vol. 147.	<input type="checkbox"/>
SY	12	SOMAN G., et al. "Aromatic Compounds as Allosteric Inhibitors of Glycogen Phosphorylase b," Biochimica et Biophysica Acta, 1974, 359-362, Vol. 358.	<input type="checkbox"/>
SY	13	ROSAUER K.G., et al., "Novel 3,4-Dihydroquinolin-2(1H)-one Inhibitors of Human Glycogen Phosphorylase a," Bioorganic & Medicinal Chemistry Letters, 2003, 4385-4388, Vol. 13.	<input type="checkbox"/>
SY	14	TEAGUE J. et al., "Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat," Diabetes, 53, Supp. 2, 2004, A365, 1521-P.	<input type="checkbox"/>
SY	15	VERTIGAN H. et al., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents," Diabetologia, 2004, A214, 589, Vol. 47, Supp.1.	<input type="checkbox"/>
SY	16	FONT M. et al. "Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase", European Journal Med Chem, 1995, 963-71, Vol. 30.	<input type="checkbox"/>
SY	17	LIN T. et al. "Effects of Protein Binding and Experimental Disease States on Brain Uptake of Benzodiazepines in Rats", J Pharmacology & Eptl Therapeutics, 1990, 45-50, Vol. 253(1).	<input type="checkbox"/>
SY	18	VARNAVAS A. et al. "Quinolone Derivatives: Synthesis and Binding Evaluation on Cholecystokinin Receptors", Il Farmaco, 1996, 341-350, Vol. 51(5).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10567801
Filing Date		2006-02-09
First Named Inventor	Bennett	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number		101181-1P US

SY	19	PARSONS W H. et al. "Cholecystokinin Antagonists. Synthesis and Biological Evaluation of 3-Substitued Benzolactams", J Med Chem, 1989, 1681-5, Vol. 32.	<input type="checkbox"/>
SY	20	FREEMAN S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor," Diabetes, 52, Supp., 2003, A340, 1470-P.	<input type="checkbox"/>
SY	21	TURNBULL A., et al., "Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes," Diabetes, 52, Supp., 2003, A343, 1485-P.	<input type="checkbox"/>
SY	22	BIRCH A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, Cambridge Med Chem Symposium, Sept 2003.	<input type="checkbox"/>
SY	23	HUDSON S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 2002, 52-53, Vol. 539.	<input type="checkbox"/>
SY	24	VERTIGAN H. et al., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents", EASD Munich, 2004.	<input type="checkbox"/>
SY	25	BARTLETT J. et al., "In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase", ADA San Diego, 2005.	<input type="checkbox"/>
SY	26	BENNETT S N L. et al., "Novel Orally Active Amino-indan Inhibitors of Glycogen Phosphorylase", Cambridge Med Chem Conference, Sept 2005. Poster EOM.	<input type="checkbox"/>
SY	27	GREEN A R. et al., "The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation", J Biol Chem, 2004, 46474-46482, Vol. 279(45).	<input type="checkbox"/>
SY	28	ROBERTS P A. et al., "The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle", J Physiology, 2002, 297-304, Vol. 545(1).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10567801
Filing Date	2006-02-09
First Named Inventor	Bennett
Art Unit	
Examiner Name	Not yet assigned
Attorney Docket Number	101181-1P US

EXAMINER SIGNATURE

Examiner Signature	/Shawquia Young/	Date Considered	01/08/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

IDS - 06/12/2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10567801
Filing Date	2006-02-09
First Named Inventor	Bennett
Art Unit	
Examiner Name	Not yet assigned
Attorney Docket Number	101181-1P US

U.S. PATENTS

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
SY	1	20040002495	A1	2004-01-01	Philip Sher et. al.	
SY	2	20040082641	A1	2004-04-29	Klaus Asger Rytved et. al.	
SY	3	20040142938	A1	2004-07-22	Philip M. Sher et. al.	
SY	4	20040220229	A1	2004-11-04	Donald L. Bussolotti et. al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
-------------------	---------	--------------------------------------	---------------------------	------------------------	------------------	---	--	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10567801
Filing Date		2006-02-09
First Named Inventor	Bennett	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number	101181-1P US	

SY	1	02/96864	WO	A1	2002-12-05	Aventis Pharma Deutschland GmbH	<input checked="" type="checkbox"/>
SY	2	02/98348	WO	A2	2002-12-12	Eli Lilly and Company	<input type="checkbox"/>
SY	3	03/037864	WO	A1	2003-05-08	Japan Tobacco Inc.	<input checked="" type="checkbox"/>
SY	4	03/045920	WO	A1	2003-06-05	Merck & Co., Inc.	<input type="checkbox"/>
SY	5	03/072570	WO	A1	2003-09-04	Pfizer Products Inc	<input type="checkbox"/>
SY	6	03/074484	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
SY	7	03/074485	WO	A2	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
SY	8	03/074513	WO	A2	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
SY	9	03/074517	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
SY	10	03/074531	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>
SY	11	03/074532	WO	A1	2003-09-12	AstraZeneca AB	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10567801
Filing Date		2006-02-09
First Named Inventor	Bennett	
Art Unit		
Examiner Name	Not yet assigned	
Attorney Docket Number		101181-1P US

SY	12	03/091213	WO	A1	2003-11-06	Yamanouchi Pharmaceutical Co., Ltd.	<input checked="" type="checkbox"/>
SY	13	2004/031193	WO	A1	2004-04-15	AstraZeneca AB	<input type="checkbox"/>
SY	14	2004/031194	WO	A1	2004-04-15	AstraZeneca AB	<input type="checkbox"/>
SY	15	2004/041780	WO	A2	2004-05-21	Pfizer Products Inc.	<input type="checkbox"/>
SY	16	2004/078743	WO	A1	2004-09-16	Aventis Pharma Deutschland GMBH	<input checked="" type="checkbox"/>
SY	17	2004/092158	WO	A1	2004-10-28	Pfizer Products Inc	<input type="checkbox"/>
SY	18	2004/104001	WO	A2	2004-12-02	OSI Pharmaceuticals, Inc.	<input type="checkbox"/>
SY	19	2004/113345	WO	A1	2004-12-29	Japan Tobacco Inc.	<input checked="" type="checkbox"/>
SY	20	2005/013975	WO	A1	2005-02-17	AstraZeneca AB	<input type="checkbox"/>
SY	21	2005/013981	WO	A1	2005-02-17	AstraZeneca AB	<input type="checkbox"/>
SY	22	2005/019172	WO	A1	2005-03-03	AstraZeneca AB	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10567801	
Filing Date		2006-02-09	
First Named Inventor	Bennett		
Art Unit			
Examiner Name	Not yet assigned		
Attorney Docket Number		101181-1P US	

SY	23	2005/020985	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>
SY	24	2005/020986	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>
SY	25	2005/020987	WO	A1	2005-03-10	AstraZeneca AB		<input type="checkbox"/>
SY	26	2005/067932	WO	A1	2005-07-28	Janssen Pharmaceutica, N.V.		<input type="checkbox"/>
SY	27	2005/085194	WO	A2	2005-09-15	Prosidion Limited		<input type="checkbox"/>
SY	28	2005/085245	WO	A1	2005-09-15	Prosidion Limited		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Shawquia Young/	Date Considered	01/08/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10567801
Filing Date	2006-02-09
First Named Inventor	Stuart Norman Lile Bennett
Art Unit	1626
Examiner Name	Young, Shawquia
Attorney Docket Number	101181-1P US

U.S. PATENTS

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

[Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵